JP2011207882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011207882A5 JP2011207882A5 JP2011075243A JP2011075243A JP2011207882A5 JP 2011207882 A5 JP2011207882 A5 JP 2011207882A5 JP 2011075243 A JP2011075243 A JP 2011075243A JP 2011075243 A JP2011075243 A JP 2011075243A JP 2011207882 A5 JP2011207882 A5 JP 2011207882A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- absent
- antibody
- administering
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052717 sulfur Inorganic materials 0.000 claims 23
- 229910052727 yttrium Inorganic materials 0.000 claims 23
- 238000000034 method Methods 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 18
- 229910052720 vanadium Inorganic materials 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 229910052731 fluorine Inorganic materials 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 9
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 9
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 229910052721 tungsten Inorganic materials 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000027455 binding Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000002222 hemangioblastoma Diseases 0.000 claims 2
- 201000011066 hemangioma Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 230000008728 vascular permeability Effects 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62016104P | 2004-10-19 | 2004-10-19 | |
| US60/620,161 | 2004-10-19 | ||
| US10/982,440 | 2004-11-04 | ||
| US10/982,440 US7658924B2 (en) | 2001-10-11 | 2004-11-04 | Angiopoietin-2 specific binding agents |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538066A Division JP2008520188A (ja) | 2004-10-19 | 2005-10-19 | アンジオポエチン−２特異的結合物質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013190316A Division JP2014040428A (ja) | 2004-10-19 | 2013-09-13 | アンジオポエチン−２特異的結合物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011207882A JP2011207882A (ja) | 2011-10-20 |
| JP2011207882A5 true JP2011207882A5 (pt) | 2012-06-21 |
Family
ID=39608222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538066A Pending JP2008520188A (ja) | 2004-10-19 | 2005-10-19 | アンジオポエチン−２特異的結合物質 |
| JP2011075243A Withdrawn JP2011207882A (ja) | 2004-10-19 | 2011-03-30 | アンジオポエチン−２特異的結合物質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538066A Pending JP2008520188A (ja) | 2004-10-19 | 2005-10-19 | アンジオポエチン−２特異的結合物質 |
Country Status (10)
| Country | Link |
|---|---|
| JP (2) | JP2008520188A (pt) |
| CN (1) | CN101495513B (pt) |
| BR (1) | BRPI0518209A (pt) |
| EA (1) | EA011866B1 (pt) |
| IL (1) | IL182279A0 (pt) |
| MA (1) | MA29015B1 (pt) |
| MX (1) | MX2007004247A (pt) |
| RU (2) | RU2404992C2 (pt) |
| SG (1) | SG156668A1 (pt) |
| ZA (1) | ZA200704020B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0518209A (pt) * | 2004-10-19 | 2008-11-04 | Amgen Inc | agentes de ligação especìficos à angiopoietina-2 |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EA022546B1 (ru) * | 2011-09-28 | 2016-01-29 | Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук | Способ торможения роста карциномы эрлиха у лабораторного животного |
| EP2760471B9 (en) * | 2011-09-30 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| WO2013112438A1 (en) * | 2012-01-23 | 2013-08-01 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ang2 antibodies |
| WO2014100834A1 (en) * | 2012-12-21 | 2014-06-26 | The Regents Of The University Of California | Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity |
| JP6411379B2 (ja) | 2013-05-14 | 2018-10-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| ES2926687T3 (es) | 2014-08-28 | 2022-10-27 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y método para su producción |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN106512006A (zh) * | 2016-07-25 | 2017-03-22 | 广州道瑞医药科技有限公司 | Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用 |
| CN106075448A (zh) * | 2016-07-25 | 2016-11-09 | 广州道瑞医药科技有限公司 | Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用 |
| CN109096368B (zh) * | 2018-09-30 | 2021-07-20 | 华南理工大学 | 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用 |
| AU2020227580A1 (en) * | 2019-02-25 | 2021-09-30 | Pharmabcine Inc. | Anti-Ang2 antibody and use thereof |
| CN112126671B (zh) * | 2020-08-18 | 2021-08-31 | 中山大学附属第五医院 | 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用 |
| CN116265487A (zh) * | 2021-12-16 | 2023-06-20 | 三优生物医药(上海)有限公司 | 抗ang2-vegf双特异性抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2368670C (en) * | 1999-03-26 | 2012-06-05 | Chitra Suri | Modulation of vascular permeability by means of tie2 receptor activators |
| US7205275B2 (en) * | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| EP1458367B2 (en) * | 2001-10-12 | 2021-01-27 | Aquestive Therapeutics, Inc. | Uniform films for rapidly dissolving dosage form incorporating taste-masking compositions |
| BRPI0518209A (pt) * | 2004-10-19 | 2008-11-04 | Amgen Inc | agentes de ligação especìficos à angiopoietina-2 |
-
2005
- 2005-10-19 BR BRPI0518209-3A patent/BRPI0518209A/pt not_active IP Right Cessation
- 2005-10-19 MX MX2007004247A patent/MX2007004247A/es active IP Right Grant
- 2005-10-19 EA EA200700876A patent/EA011866B1/ru not_active IP Right Cessation
- 2005-10-19 JP JP2007538066A patent/JP2008520188A/ja active Pending
- 2005-10-19 SG SG200907008-7A patent/SG156668A1/en unknown
- 2005-10-19 CN CN200580043569.5A patent/CN101495513B/zh not_active Expired - Fee Related
- 2005-10-19 RU RU2007118670/13A patent/RU2404992C2/ru not_active IP Right Cessation
-
2007
- 2007-03-28 IL IL182279A patent/IL182279A0/en unknown
- 2007-05-11 MA MA29892A patent/MA29015B1/fr unknown
- 2007-05-18 ZA ZA200704020A patent/ZA200704020B/en unknown
-
2010
- 2010-08-05 RU RU2010132956/10A patent/RU2010132956A/ru not_active Application Discontinuation
-
2011
- 2011-03-30 JP JP2011075243A patent/JP2011207882A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011207882A5 (pt) | ||
| CA2583910A1 (en) | Angiopoietin-2 specific binding agents | |
| RU2007118670A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| JP2013502913A5 (pt) | ||
| JP2020500003A5 (pt) | ||
| JP2014511179A5 (pt) | ||
| JP2022101693A5 (pt) | ||
| JP2017507652A5 (pt) | ||
| JP2013506428A5 (pt) | ||
| JP2009225799A5 (pt) | ||
| JP2019527194A5 (pt) | ||
| RU2015141428A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| JP2020504076A5 (pt) | ||
| JP2022020666A (ja) | 改善されたｔｎｆ結合因子 | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP2019505527A5 (pt) | ||
| JP2014527814A5 (pt) | ||
| JP2014503202A (ja) | ＴＮＦ−α結合性タンパク質 | |
| JP2015503909A5 (pt) | ||
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| JP2013519367A5 (pt) | ||
| JP2010527939A5 (pt) | ||
| JPWO2021139777A5 (pt) | ||
| JP2020522488A5 (pt) |